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ABSTRACT

MEASURING THE EFFECTS OF LOBINALINE-N-BIOXIDE (419) ON ALCOHOL
CONSUMPTION, NICOTINE LOCOMOTOR SENSITIZATION, AND CONDITIONED
PLACE PREFERENCE IN MICE AND RATS
Objective: Novel drug 419 was examined to see the effect it has in vivo mice and rats on alcohol
consumption, nicotine locomotor sensitization, and conditioned place preference (CPP) models
regarding behavioral tests on dopamine transporter activity.
Methods: Mice and rats were used to see how they react to the drug 419 and control vehicle, in
each of the models. The animals were assessed to pre- and post- drug administration of novel
drug 419. We examined each model to see the association between how drug 419 will help with
treating drug abuse.
Results: We found that in alcohol consumption model the mice did not react well to drug 419
and had no significant results. In the nicotine locomotor sensitization, we found that drug 419
has potential in reversing the nicotine induced locomotor activity and could help reduce nicotine
abusive disorder. The CPP model did not have any significant results in either rat group. We
found that drug 419 at the dose we administered does not seem to have a significant effect in the
mesolimbic dopaminergic pathways and may not facilitate a role in treating drug abuse.
Conclusion: Our findings suggest that drug 419 may play a role in only nicotine locomotor
sensitization due to the reversal of nicotine induce LMA that was observed. The use of drug 419
in alcohol consumption and CPP models indicated that it is not effective as it did not alter the
behavior in mice and rats. The need for understanding the pharmacological and
pharmacokinetics of drug 419 is critical to fully be implemented in future behavioral tests.
KEYWORDS: Lobinaline-N-Bioxide, 419, Alcohol Consumption, Nicotine Locomotor
Sensitization, Conditioned Place Preference
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CHAPTER I
Introduction
In the past few years, several studies have demonstrated how drug abuse has led to
behavioral issues. An issue that has now become a problem in the United States. The most recent
report by the National Institute on Drug Abuse states that there are an estimated 2.1 million
people in the United States that have a substance use disorder such as, prescription opioid
medicine and heroin use (NIDA, 2020). There are certain effective prevention and treatment
strategies that have been implemented but are severely underutilized across the United States
thus, leading to drug abuse issues (NIDA, 2020). There are many studies showings that various
drugs such as methadone, naloxone, and naltrexone are good at reducing the risk of behavior
associated with drug abuse (NIDA, 2020). It has also been observed that drug abuse has
increased regarding nicotine and alcohol (Zago et al., 2012).
In many studies there seems to be a link between drug abuse and addiction because of the
reward neurotransmitter dopamine (Perna and Brown, 2013). Many preclinical and
epidemiological studies have shown that alcohol and nicotine-containing tobacco products tend
to have high rates of co-abuse (Gubner and Phillips, 2015). It has been observed that alcohol and
nicotine do cause enhanced activation of the mesolimbic dopamine systems (Gubner and
Phillips, 2015). The activation of this mesolimbic dopamine systems has been strongly
associated in facilitating drug craving and reward, as well as playing a role in the drug-induced
locomotor stimulation (Gubner and Phillips, 2015). Furthermore, it may be possible that ethanol
and nicotine in combination may cause greater activation of brain pathways involved in drug
reward and neuroadaptation caused by either drug alone (Gubner and Phillips, 2015). In human
1

studies it was observed that nicotine triggers the rewarding and reinforcing effects inducing
behavioral changes (Philpot et al., 2012).
In models of alcoholism, it appears that many various neurotransmitter systems are
affected and have neurobiological basis for alcohol reward (Dudek and Hyytiaj, 2016). In this
current study, the aim is to evaluate lobinaline-N-bioxide (419), derived from L. cardinalis plant
may help with behavioral tests. This study examined drug 419’s efficacy on dopamine
transporter activity and the effects of alcohol and nicotine within the dopamine pathway. This
study examined drug 419 on how it may help reduce the mesolimbic dopamine systems as well
as potentially reducing drug reward and cravings. The aim of this project is to see how drug 419
will react in vivo animals in alcohol consumption, nicotine locomotor sensitization, and
conditioned place preference behavioral tests.
Plant Synthesis
Plants have lots of medicinal properties that have provided humans with treatments for
various diseases and adverse health conditions for ages. Humans have found rich sources of
metabolites and natural products in plants that have led to creating novel drugs (Brown et al.,
2016). The pharmaceutical industry has relied on plants to derive and synthesize plant-based
medicines (Brown et al., 2016). However, in recent years the pharmaceutical industry has
increasingly abandoned the use of plants as a potential source of pharmaceutical derivatives
(Brown et al., 2016). A complex chemical synthesis is often required to convert bioactive plant
metabolites into optimal drug targets making it a less commonly used process (Brown et al.,
2016). In recent years, pharmaceutical companies have begun to use cultured plant cells as
production systems to create effective drug metabolites (Brown et al., 2016).
2

In order to target proteins for metabolic activity, a plant species is identified and used
(Brown et al., 2016). Complex metabolites within plant species are examined and determined if
compatible with the target protein of interest (Brown et al., 2016). After this the transgenic plant
cell is created, then examined how stable the target protein can be, and then tested to determine
the interaction between the plant cell and target protein (Brown et al., 2016). This allows to
create mutant transgenic cells and that can then provide metabolites that have appropriate
pharmacological activity (Brown et al., 2016). These new metabolites are then used to create
“novel” active metabolites that can enhance activity of the target protein (Brown et al., 2016).
This form of pharmacotherapy has been implemented for the treatment of drug abuse and
most of these treatments are from plant derived products (Brown et al., 2016). Plants have given
humans many important secondary metabolites that have led to drug discovery (Hussain et al.,
2012). By using plant secondary metabolites, it has allowed researchers to target various
proteins, macromolecules, molecular target direct proteins, and many other structures in humans
for medicinal proposes (Hussain et al., 2012). The use of these metabolites has led researchers to
better understand the structural optimization for drugs, to create drugs, and to make these drugs
suitable for treating disease (Hussain et al., 2012).
In this study we used previous research by Brown et al. (2016), who created a plant-based
drug that targeted human dopamine transporter that was functional expressed in Lobelia
cardinalis (Brown et al., 2016). The plant L. cardinalis was used because of the complex binitrogenous decahydroquinoline alkaloid, low potency to dopamine transporter inhibitor, and
cannot be synthesized in a laboratory (Brown et al., 2016). The use of lobinaline was
implemented in this study to gain insight on how target-direct the drug 419 will be and how it
will respond to the behavior models with respect to dopaminergic neurons.
3

Lobinaline
The study by Brown et al. (2016) used high-throughput pharmacological screening
(HTPS) to measure plant extract’s bind to nicotinic acetylcholine receptor (nicAchR) ligands for
drug and pharmacological use (Brown et al., 2016). The researchers used L. cardinalis to
understand what binding and active metabolites this plant provides (Brown et al., 2016). The
extract from L. cardinalis led to understanding of how various nicAchR ligands and dopamine
transporters (DAT) are impacted (Brown et al., 2016). The plant L. cardinalis has alkaloids that
seem to inhibit DAT and may play a role in neuroprotective abilities (Brown et al., 2016). From
the extract of L. cardinalis, it was found that lobinaline is the key metabolite that has
neuroprotective capabilities (Brown et al., 2016).
Lobinaline is a major metabolite from L. cardinalis and has proven to have
multifunctional pharmacological impacts (Brown et al., 2016). It has been found that lobinaline
is a complex decahydroquinoline alkaloid that can function as a nicAchR agonist, free radical
scavenger, and DAT inhibitor (Brown et al., 2016). The structure of lobinaline was confirmed
from chromatographic peak and can be seen in Figure 1, which shows that complex
binitrogenous alkaloid (Brown et al., 2016). However, the full pharmacological effects of
lobinaline have been unreported and must be studied to attain the effects of lobinaline.
A study by Brown et al. (2016), found that lobinaline effects nicAchR and may inhibit
dopamine uptake in vivo rats (Brown et al., 2016). Lobinaline seems to inhibit binding of the
nicAchR selective ligand in rat cortical and hippocampal membrane (Brown et al., 2016). The
ability of lobinaline to be a nicAchR agonist have been observed, but the data does not show how
lobinaline appears to distinguish from nicotine and lobeline for selective and functional effects of
4

nicAchR (Brown et al., 2016). Further studies need to assess how lobinaline can effectively
target nicAchR and if it can be a full or partial agonist. Regarding lobinaline interacting with
dopamine transport, rat striatal membranes were collected and analyzed (Brown et al., 2016). It
was found that lobinaline seems to help reduce exogenous dopamine levels and likely may
function as a DAT inhibitor (Brown et al., 2016).
Lobinaline has the ability to be a multifunctional drug that may help in nicAchR agonist
and DAT inhibition, but further research is needed. Lobinaline does have promising
pharmacological effects in preventing neurotoxicity as seen in psychostimulant abuse and
Parkinson’s disease (Brown et al., 2016). The ability of lobinaline to be a DAT inhibitor is
promising because of its ability to help reduce neurotoxicity caused by amphetamines (Brown et
al., 2016). Lobinaline also has potential as a nicAchR agonist to have neuroprotective ability in
cellular and animal models examining Parkinson’s disease (Brown et al., 2016). The ability of
lobinaline to be a multi-functional drug paves way to understand how it plays a role in behavioral
studies in relation to reward and motor effects (Brown et al., 2016).
In this current study, we examine the motor stimulatory and behavioral aspects of
lobinaline using in vivo models to gain insight on this drug. In this study, we acquired a
lobinaline derivative that has a different molecular weight and structure known as lobinaline-nbioxide (419) and we hypothesized that drug 419 may have similar functions as lobinaline. We
examined what effects drug 419 had regarding behavioral tests by using alcohol consumption,
nicotine locomotor sensitization, and conditioned place preference in rat and mice models.

5

Figure 1: Structure of lobinaline. Red circles denote chiral center (Brown et al., 2016).
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Pharmacological inhibition of dopamine transporter (DAT)
Dopamine (DA) is an important neurotransmitter that tends to play a role in the “brain
reward circuit” (Zahniser and Sorkin, 2004). Dopamine also plays a role in locomotor activity,
motivation, reward, and cognition (Bannon, 2005). Dopamine also plays a role in psychomotor
stimulant behavioral activation and reward (Zahniser and Sorkin, 2004). Drug such as
amphetamine or methamphetamines tend to affect dopamine transporter (DAT), which plays an
important role in dopaminergic signaling, reward pathways, and substance abuse (Tang et al.,
2015). DAT is a plasma membrane protein and is important for dopamine synthesizing neurons
(Bannon, 2005). The DAT is a dopaminergic regulator in the striatum and nucleus accumbens
that target cocaine and methamphetamine (Brown et al., 2016). These drugs tend to affect the
DAT that cause an increase in extracellular dopamine (Tang et al., 2015). Cocaine tends to be a
DAT inhibitor and enriches DA release (Brown et al., 2016). Methamphetamine is a substrate of
the DAT that inhibits DA reuptake and reallocates DA to cause increase in cytosolic DA (Brown
et al., 2016).
Drugs such as lobinaline have shown to inhibit DAT and can be helpful in treating drug
abuse (Brown et al., 2016). DAT plays a role in modifying human behavior and can help with
drug abuse treatments. In this study we examined how lobinaline-N-bioxide (419) may have
potential for inhibiting DAT and could be viable for treating drug abuse. We examined what
effects drug 419 will have and hypothesized that it will inhibit DAT in rat and mice models due
to the similar characteristic found in lobinaline.
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Alcohol Consumption
Alcohol has been known to be one of the most used substances and is commonly coadministered with many different types of drugs (Winkler et al., 2018). Alcohol and
polysubstance use have risen in the past years with about 75 percent of emergency room visits to
be associated with this issue (Winkler et al., 2018). The use of various polysubstance and alcohol
has become very common, but there seems to be little research in understanding the combined
effects of various drugs to alcohol (Winkler et al., 2018). Recent studies indicate that alcohol is
often co-used with psychostimulants and illicit drug use consequently, leading to drug abuse
(Winkler et al., 2018). It has been found that alcoholism is a chronic psychiatric disorder that has
neuroanatomical and neurochemical effects (Dudek and Hyytiä, 2016). Many extensive studies
indicate that alcohol drinking changes neural circuitry by inducing alcohol reinforcement (Dudek
and Hyytiä, 2016).
Alcohol consumption mediates the release of dopamine from the ventral tegmental
(VAT) neurons that then project to the nucleus accumbens (Touchette et al., 2018). Alcohol
consumption has a neuro-molecular mechanism that involves the nicotine acetylcholine receptors
(nicAChrs), located on neuronal cells bodies and presynaptic terminals (Touchette et al.,
2018). The activation of the nicAChrs leads to the excitation of the VAT dopaminergic neurons
that release dopamine, which plays a role in the reward circuitry of the brain (Touchette et al.,
2018). In some studies, it has been found the rats and mice that consume alcohol voluntarily tend
to have increased levels of acetylcholine inducing cholinergic signaling and leading dopamine
release; thereby, activating alcohol reward behavior in rats and mice (Touchette et al., 2018).
This indicates that the cholinergic signaling via nicAChrs is an important component of alcohol
addiction (Touchette et al., 2018). Furthermore, rats and mice that freely consume high amounts
8

of alcohol tend to show behavioral disinhibition and have various neurotransmitter systems due
to alcohol actions (Dudek and Hyytiä, 2016). Many rodent lines tend to have differential alcohol
preference which can provide predictive validity for novel pharmacological therapies for alcohol
abuse (Sommer et al., 2006).
Alcohol tends to create a dependence in many rodent models and create binge-like
ethanol drinking habits (Thiele and Navarro, 2014). In order to understand how ethanol plays a
role in the rodent model of binge-like drinking, the “drinking in the dark” (DID) paradigm is
often used (Thiele and Navarro, 2014). The use of DID allows for researchers to investigate how
rodent models will drink alcohol in a reverse light cycle (Thiele and Navarro, 2014). In DID the
rodents tend to drink more ethanol at dark cycle because of their increased activity levels causing
high levels of ethanol intake (Thiele and Navarro, 2014). The use of DID is implemented
because it does not require extensive training and allows for rapid screening of pharmacological
targets (Thiele and Navarro, 2014). The DID paradigm is a useful tool for studying neurobiology
and pharmacology due to the ethanol-binge-like behavior that can be easily measured (Thiele
and Navarro, 2014).
Here, we aim to use lobinaline-N-bioxide (419), as insight into the treatment of excessive
alcohol drinking and control in C57BL/6 mice by examining behavioral tests to see the effects of
drug 419 on dopamine transporter activity. C57BL/6 mice will help in understanding how
alcohol consumption in the dark plays a role in the “drinking-in-the-dark” (DID) paradigm and
how the administration of drug 419 indicates possible trends in the reduction of alcohol intake. In
clinical research it has been found that rodent models involved in voluntary consumption of
ethanol allow for better understanding of alcohol abuse (Thiele and Navarro, 2014). We will use
DID to understand the efficacy of drug 419 in relation to reduction of alcohol intake in mice.
9

Nicotine Locomotor Sensitization
In several studies it has been observed that nicotine leads to sensation-seeking behavior
and rewarding effects (Philpot et al., 2012). Nicotine produces a rewarding effect by acting on
the nicotinic acetylcholine receptors (nAChRs) (Barbosa-Méndez et al., 2017). Nicotine leads to
increasing neurotransmission in the mesolimbic and nigrostriatal dopaminergic pathways
(Barbosa-Méndez et al.,2017). In order to understand how nicotine effects behavioral
sensitization, nicotine-induced locomotor sensitization activity models are typically used
(Barbosa-Méndez et al., 2017).
The nicotine locomotor sensitization models measure and understand how repeated
administration of nicotine causes behavioral sensitization in adult rats (Zago et al., 2012). It has
been found that by administering nicotine in animal models, the response is positive and have
increased locomotor activity due to the interaction of the drug (Thompson et al., 2018). The
locomotor sensitization leads to up-regulations of brain nicotinic acetylcholine receptors
(nAChRs) and produces locomotor sensitization (Thompson et al., 2018).
In this study, we will administer drug lobinaline-N-bioxide (419) and examine the effects
in vivo behavioral tests in rats. We aim to administer nicotine via subcutaneous route in rats at a
low dose to see the effects in the locomotor stimulation model. We hypothesize that the low
doses of nicotine will cause locomotor stimulation and release dopamine in the nucleus
accumbens. We believe that daily administration of nicotine will create “sensitization” in rats
and will lead to modification of nicAChR and DAT inhibition. This behavior will allow for
proper screening of potential value in smoking cessation. We predict by injecting drug 419 after
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sensitization in rats, that the effects of nicotine on locomotion will inhibit nicAChR partial
agonist and DAT activities.
Conditioned Place Preference (CPP)
Many studies have examined how drug abuse affects the reward circuitry of the brain and
have used various methods to gain a better understanding. It is evident that dopamine secreting
cells play an important role in activating the mesolimbic and mesocortical regions of the brain
(Vastola et al., 2002). There seems to be a correlation with dopamine receptors in the mesolimbic
and striatal brain regions in both humans and rodents that cause neurobehavioral changes
(Vastola et al., 2002). In order to understand how the neurobehavioral affects the rewarding
circuitry of the brain, conditioned place preference (CPP) model is often used (Vastola et al.,
2002).
The CPP model is used because it measures how laboratory animals will react to a drug
creating a reward value in various conditions (Vastola et al., 2002). The use of CPP allows
researchers to observe how the laboratory animals respond to social housing and behavioral
expression when given the drug of interest (Vastola et al., 2002). The CPP model allows for
testing animals in drug-free state, to assess locomotor activity, assess behavioral changes, and
does not require a lot of training time (Vastola et al., 2002). Most CPP models examine the
rewarding properties of a drug and how dose-dependency may play a role in the rewarding
properties for the drug of interest (Vastola et al., 2002). A standard CPP model includes a special
chamber that has two or three compartments with different colors, floors, and designs to
distinguish between compartments (Vastola et al., 2002). In a CPP model, the animals are given
a series of sessions to get acclimated to the compartment and then tested in the opposite
11

compartment with the drug of interest being administered (Vastola et al., 2002). The drug is
intended to be rewarding for the animals and the animals will spend more time in the drug
administered compartment (Vastola et al., 2002). This method will show if the drug that is
administered will indeed be a conditioned place preference (Vastola et al., 2002).
In this study, we administered drug lobinaline-N-bioxide (419) and examined the effects
in vivo neurobehavioral tests in rats. We administered drug 419 via subcutaneous route in rats at
a low dose to see the effects in the CPP model. We hypothesized that the low doses of drug 419
will cause it to be a rewarding drug for rats and the rats will spend more time in the drug
administered compartment. This behavior allowed for proper screening of potential value for
drug abuse and to observe if drug 419 will create any significant effects.
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Statement of Hypothesis
The purpose of this thesis is to understand and investigate the interaction of lobinaline-Nbioxide (419) on alcohol consumption, nicotine locomotor effects, and conditioned place
preference in rats and mice. The use of rats and mice were chosen due to previous studies
showing how these animals responded to Lobelia cardinalis with respect to alcohol, nicotine,
and CPP. In previous studies, it was also found that L. cardinalis has a unique pharmacological
effect in treatment of drug abuse and dopaminergic neurodegeneration (Brown et al., 2016). To
understand and investigate these relationships, drug 419 was used to see how rats and mice
respond to the three experiments.
We hypothesized that during these experiments both the rats and mice will react
differently to drug 419 and may have a significant response to alcohol consumption, nicotine
locomotor effects, and CPP. The use of drug 419 is critical to understand the dose response in
rats and mice due to its correlation to human dopamine transporter. Thus, allowing drug 419 to
become a possible pharmaceutical target for drug abuse. Drug 419 will give new evidence for
how this drug targets various molecular proteins, how it can be used in target-directed
biosynthesis, and how it can be used as drug treatment in drug abuse therapies.

13

Chapter II
Materials and Methods
Experiment 1: Effects of 419 on alcohol consumption (DID)
Purpose
Lobinaline n-bioxide (419) may have certain pharmacological benefits if given at correct
doses and here, we examined how it affects alcohol consumption. The use of drug 419 will help
examine the effects of how alcohol consumption can be altered due to the response alcohol has in
dopamine transporter activity. The administration of drug 419 will change alcohol consumption
behavior in rats and in turn affect the dopamine transporter activity. The literature will focus on
how drug 419 will affect alcohol consumption in vivo in adolescent rats via the use of the
“drinking-in-the-dark” paradigm.
Animal and Housing
C57BL/6 male mice (n=8; commercial vendor [Envigo], transferred to University of
Kentucky) and C57BL/6 female mice (n=8; commercial vendor [Envigo], transferred to
University of Kentucky) were used. Mice ranged in age from 3 to 6 months old and weighed
from 20 g to 30 g at the start of the study. Each mouse was given a unique identification (tail
markings) for dosing and experimental use for study records. The use of the unique identification
allowed for proper dosing and documentation for study records. The mice had access to food and
water in home cages for the duration of the experiment. The procedures were performed in
accordance with the appropriate standard operating protocol in use by “University of Kentucky
Division of Laboratory Animal Resources (DLAR)”, and this is fully accredited by the
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Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). When
the mice arrived at DLAR, they were given an acclimation period of 2 weeks to the reverse light
cycle. Throughout the course of the experiments, if any adverse consequences resulted from
administration of the drug or procedures, a qualified member of the veterinary staff at University
of Kentucky was notified.
The animals were housed in proper plastic boxes with soft bedding and maintained in a
12-hour light/12-hour dark cycle at University of Kentucky DLAR facility. The rooms were
temperature-controlled and humidity-controlled rooms. The boxes contained enrichment items
and were maintained on a regular basis. The mice were chosen for the experiment because of the
acceptance and usefulness as a model in laboratory research. The 16 mice were not randomized,
each mouse received the same test article at the same dose and had the same route of
administration of drug 419, as well as the control vehicle. Although this study does not have
control groups, each mouse received the same doses and route of administration of drug 419 and
the control to be 10% DMSO/saline.
The mice were fed a standard, commercial diet of Harlan Teklad Global 18% protein
rodent diet. The local tap water was available ad libitum via automated watering bottles or
watering systems. From the experiment it is reasonable to state that no contaminants were
suspected in the diet or water that would have affected the outcome of the experiments. At the
end of the study, the animals are kept till data analysis is complete. After completion of data
analysis, the animals were offered to UK research community before euthanasia is administered.
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Euthanasia
If any animal or animals show any signs of distress due to unpredicted side effects from
drug 419 or ethanol overdose, they will be euthanized immediately and reported to the Study
Director. These animals will be euthanized by using pentobarbital sodium overdose (>100
mg/kg). The animal residual carcasses will be disposed of by the University of Kentucky
Division of Laboratory Animal Resources. If in the event any animal distress is observed during
the study both the Director and Sponsor will be notified.
Drug
There were sufficient quantities of lobinaline-N-bioxide (419) that was provided by
Naprogenix Inc (Lexington, KY). When the test article arrived at University of Kentucky, it was
inventoried and stored under desiccation at -20°C or as instructed by Naprogenix Inc. The drug
419 was provided to the University of Kentucky at the GLP Neuroscience center in Lexington,
Kentucky. The route of administration for this drug was subcutaneously (SC) and all protocols
recommended by DLAR and UKY procedure were adhered to. The drug 419 is diluted with a
10% DMSO/saline to be able to be administered for a 25-gram mouse.
Statistical Analyses
All the data sets were analyzed on how much ethanol was consumed and analyzed via
one-way Analysis of Variance (ANOVA) with Bonferroni post-hoc comparisons. The ANOVA
will show the repeated measures with all 6 days vs 419 vs vehicle. The data will show what the
P-value is, the matching effectiveness, and will allow 4 days of baseline repeated measure
ANOVA. All tests will be statistical significance at p<0.05.
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Study Modifications and Record Retention
During the study if the need for any modification occurred it was made with verbal or
written consent by the Study Director. If verbal authorization was given it was documented in the
raw data and was followed with a written protocol amendment within 10 business days. If the
need for any amendments or deviations occurred to the study protocol it was documented, dated,
signed by the Study Director, and maintained in the study protocol. If any of these amendments
needed to occur, it was also approved by the Sponsor. When the issuance of the final report to
the Study Sponsor, all the raw data and specimens relating to the study generated by University
of Kentucky are retained for up to 1 year in the test facility archives. The test facility archives
staff will contact the Sponsor after 1 year to determine the disposition of the archived materials.
Portions of the study conducted by the sponsor or sponsor’s designee will be archived in the
storage facilities of the sponsor or sponsor’s designee.
Experimental Design
The “drinking-in-the-dark” paradigm is a well-recognized model for understanding how
mice binge drink alcohol in the dark (Crabbe et al., 2019). In recent studies it has been noted
that mice tend to be more useful for not only genetic studies but for disorders such as alcoholism
(Rhodes et al., 2005). In mice model studies when ethanol and water were given to mice, the
mice tend to have strong self-administration for drinking ethanol (Rhodes et al., 2005). It seems
that C57BL/6 mice on average tend to have daily fluid intake from 10% to 20% ethanol solution
over plain water (Rhodes et al., 2005). In a study that examined how rats consume ethanol, it was
observed that the rats consume ethanol in discrete sessions in the dark more than during the lightdark cycle, showing a preference for consumption of ethanol at night more (Rhodes et al.,
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2005). Rhodes et al. (2005), designed various experiments that would look at the
pharmacological significant ethanol drinking in the mice and followed a dark-light cycle to see
how the mice respond to the self-administered ethanol (Rhodes et al., 2005). Thus, in this design
of DID C57BL/6J mice were given limited access to a higher ethanol dose of (20% v/v) daily
during the dark cycle. The mice had daily repeated access and would voluntarily drink
significant amounts of ethanol with blood ethanol reaching levels above 150 mg/dl.
In order to understand the effects of drug 419 on alcohol consumption the systemic
administration of drug 419 was necessary. The use of drug 419 will inhibit the dopamine
transporter system and reduce ethanol intake by using the DID model. The C57BL/6J mice were
maintained in a reverse light/dark cycle with 12 hours in each cycle. The mice were given at least
12 days with one-hour day of light reverse cycle to acclimate before starting the experiment. The
experimental design and protocols were followed by the researchers and the staff at the DLAR in
order to help maintain the correct cycle and to limit any errors in the DID model.
Procedure
The drinking-in-the-dark protocol was used for this study and adapted to understand how
the adult inbred C57BL/6J mice will react to drug 419. This experiment was a six-day DID
model that used 16 adult C57BL at 2 to 3 months of age and were broken into gender of male
and female. The mice were grouped based on sex and separated into groups at the start of the
experiment. At least one week before experimentation began, each mouse was housed in a
standard shoebox mouse cage with mouse bedding, standard mouse chow, and water provided by
ad libitum. All the mice were housed in the same room, with the same ambient temperature, and
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had the 12-hour light/12-hour dark cycle prior to testing. These procedures helped the mice have
sufficient acclimation to DID housing conditions before any experimentation.
Before starting any experimentation, the mice were weighed using a standard
scale/balance to help get initial data and observe the change in body weight when ethanol
consumption will take place. The average weight of each mouse was determined under normal
condition at least 4 days prior to testing thus, allowing for relative stable body weight. The mice
were individually weighed out of the cage on a scale before the start of the dark cycle. By doing
this it will allow for adequate acclimation for the individual mouse and to settle down before
introducing the alcohol solution after the three hours have passed into the dark cycle. Before the
ethanol drinking period begins, the ball-bearing DID sipper tubes will be filled with 20% v/v
ethanol solution, which is 190 proof pure ethanol diluted with water. The filling of the sipper
tubes was done between the start of the dark cycle and 3 hours into the dark cycle.
When the dark cycle begins, after three hours into this cycle, the ethanol filled sipper
tubes will be introduced to the mice in the same room without any alteration to the light cycles or
temperature. The sipper tubes were set up separated from the food area and were held by a flat
stainless-steel partition. During this time the water bottles are withdrawn from each cage, the
DID sipper tube is inserted through the ring in each cage, and the tube is rested at about a 90degree angle of the wire cage top triangular indentation (same angle as that of the water bottles).
After the securing of each DID sipper tube, the reading of the meniscus is read and recorded in
the data chart. In order to get the reading this was done with a flashlight with red lens cover, so it
does not disrupt the DID cycle. The timing of all reference reading of the meniscus level of the
first DID sipper tube to have consistent data. The ethanol consumption DID model was
established for 6 days to attain baseline ethanol consumption. After establishing baseline, the
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drug 419 at 25mg/kg is administered subcutaneously (SC) at 15 minutes prior to giving ethanol
in the DID cycle. When the control vehicle was used it was also administered the same way by
using a control that is only 10% Dimethyl Sulfoxide (DMSO)/saline.
The drug 419 is diluted with 10% DMSO/saline and there will be a control vehicle that is
10% DMSO/saline. The drug 419 is diluted at 5 mg/ml so a 25 g mouse will receive its SC
volume of 0.13 ml that contains 25 mg of drug 419 and about 10 mg of DMSO. The amount of
DMSO used corresponds to 0.5 g/kg because it is non-toxic and doses up to 3 g/kg. The animals
either received the drug 419 or control vehicle and the administrator is blinded as to what drug
each animal is getting. The following day, the animals received the opposite drug and data was
recorded. The mice that are mildly drunk at 100-150 mg/ml ethanol volume were observed every
hour for 3 hours and then at the end of the day. The end of the day the elimination rate was
around 50 mg/hour. The animals will not be measured for blood ethanol concentration but only
the weight of each animal will be measured.
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Experiment 2: Effects of 419 on nicotine locomotor sensitization
Purpose
Lobinaline-N-bioxide 419 is used to examine the effects of how dopamine transporter
activity is affected. The literature will focus on how drug 419 will affect nicotine locomotor
sensitization in vivo in adult rats. The use of drug-induced stimulation will give a better
understanding of how the behavioral model will lead to activation of the drug-induced locomotor
stimulation (Gubner & Phillips, 2015). This experiment will assess the impact of nicotine versus
newly discovered drug 419 in behavioral tests on the adult rats via locomotor sensitization
model.
Animal and Housing
Male Sprague-Dawley rats (n=6; commercial vendor [Envigo], transferred to University
of Kentucky) and Female Sprague-Dawley rats (n=6; commercial vendor [Envigo], transferred to
University of Kentucky) were used. Rats ranged in age from 2 to 6 months old and weighed from
200 g to 350 g at the start of the study. Each rat was given a unique identification (tail markings)
for dosing and experimental use for study records. The use of the unique identification allowed
for proper dosing and documentation for study records. The rats had access to food and water in
home cages for the duration of the experiment. The procedures were performed in accordance
with the appropriate standard operating procedures in use by “University of Kentucky Division
of Laboratory Animal Resources (DLAR)”, and this is fully accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC).
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These adolescent rats were chosen for the study due to the usefulness and acceptances of
this model in lab research. The reason for only 12 rats is because this is the minimum necessary
amount to get valid scientific results for this study. This study did not duplicate any previous
work and does not unnecessarily replicate any previous work. The procedures used in this study
are to help avoid and minimize any stress, pain, or discomfort to the animals. Although there
were no animals in distress from this study however, if any animals experienced any pain or
distress, they were to be painlessly euthanized by the consultation of the University of Kentucky
veterinary stuff or Study Director.
The animals were also housed in proper plastic boxes with soft bedding and maintained
in a 12-hour light/12-hour dark cycle at University of Kentucky DLAR facility. The rooms were
temperature-controlled and humidity-controlled rooms from 64 °F to 84˚F and 30% to 70%,
respectively. The boxes had enrichment items in them and were maintained on a regular basis.
The 12 rats were not randomized, each mouse received the same test article at the same dose and
had the same route of administration of drug 419. When the animals arrived at the DLAR they
were given a period of about a week to get acclimated to the surroundings before any
experimentation occurred. The animals were also observed periodically during this acclimation
time to make sure no adverse or distress occurred in any of the animals. The animals were also
acclimated to handlers and researched during this one-week time. During the study, there were
no control groups, but each mouse will receive the same doses and route of administration of
drug 419 and the nicotine injection of 0.5 mg/kg SC.
The animals were fed a standard, commercial diet of Harlan Teklad Global 18% protein
rodent diet. The local tap water was available ad libitum via automated watering bottles or
watering systems. From the experiment it is reasonable to state that no contaminants were
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suspected in the diet or water that would have affected the outcome of the experiments. At the
end of the study, the animals are kept till data analysis is complete. After completion of data
analysis, the animals will be offered to UK research community before euthanasia is
administered.
Euthanasia
If any animal or animals showed any signs of distress due to unpredicted side effects
from drug 419 or nicotine overdose, they are to be euthanized immediately and reported to the
Study Director. These animals will be euthanized by using pentobarbital sodium overdose (>100
mg/kg). The animal residual carcasses will be disposed of by the University of Kentucky
Division of Laboratory Animal Resources. If in the event any animal distress is observed during
the study both the Director and Sponsor were notified.
Drug
There were sufficient quantities of lobinaline-N-bioxide (419) that was provided by
Naprogenix Inc (Lexington, KY). When the test article arrived at University of Kentucky, it was
inventoried and stored under desiccation at -20°C or as instructed by Naprogenix Inc. The drug
419 was provided to the University of Kentucky at the GLP Neuroscience center in Lexington,
Kentucky. The route of administration for this drug was subcutaneously (SC) and all protocols
recommended by DLAR and UKY procedure were adhered to. The drug 419 will be at 25 mg/kg
SC injection, drug varenicline (nicotine) at 0.5mg/Kg SC injection, and the control vehicle is
made of 10% DMSO/saline to be able to be administered SC injection. In order to understand the
effects of how nicotine plays a role on locomotor, nicotine will be administered by SC injections
of 0.5 mg/Kg prepared in sterile saline. The use of nicotine is to create a “sensitization” and see
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the progressive increase in locomotor activity over days. The nicotine used for this experiment is
for the sensitization period and each rat will receive this for 5 days and the locomotion will be
recorded for baseline data.
Statistical Analyses
All the data sets will be analyzed on how much ethanol was consumed and analyzed via
two-way Analysis of Variance (ANOVA) with Bonferroni post-hoc comparisons. The ANOVA
will show the repeated measures with all 5 days vs 419 vs the control vehicle. The data will show
what the P-value is, the matching effectiveness and baseline repeated measure ANOVA. All tests
will be statistical significance at p<0.05.
Study Modifications and Record Retention
During the study if the need for any modification occurred it was made with verbal or
written consent by the Study Director. If verbal authorization was given it was documented in the
raw data and was followed with a written protocol amendment within 10 business days. If the
need for any amendments or deviations occurred to the study protocol it was documented, dated,
signed by the Study Director, and maintained in the study protocol. If any of these amendments
needed to occur, it was also approved by the Sponsor. When the issuance of the final report to
the Study Sponsor, all the raw data and specimens relating to the study generated by University
of Kentucky are retained for up to 1 year in the test facility archives. The test facility archives
staff will contact the Sponsor after 1 year to determine the disposition of the archived materials.
Portions of the study conducted by the sponsor or sponsor’s designee will be archived in the
storage facilities of the sponsor or sponsor’s designee.
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Experimental Design
In some studies, it has been found that nicotine is rewarding and leads to drug abuse that
results in gradual increase of motor stimulant response (Zago et al., 2012). This increase in motor
stimulation and response to drugs, such as nicotine, is known as sensitization because of the
neuroadaptive processes associated with drug addiction (Zago et al., 2012). The nicotine
locomotor activity is typically measured to understand how repeated administration of nicotine
causes behavioral sensitization in adult rats (Zago et al., 2012). It has been found that by
administering drugs such as nicotine in animal models they tend to respond well and have
increased locomotor activity due to the interaction of the drug (Thompson et al., 2018). It has
been observed that locomotor sensitization leads to up-regulations of brain nicotinic
acetylcholine receptors (nAChRs) and produces locomotor sensitization (Thompson et al., 2018).
Thus, the implementation of nicotine locomotor sensitization protocol will be used for this study.
This will give a better understanding of how nicotine and drug 419 will be associated with drug
reward and give increase in locomotor activity. This experiment will help access how the adult
rats respond to nicotine and become sensitized to this drug. After the sensitization, the drug 419
is introduced to show the effects it will have regarding locomotor sensitization. It was
hypothesized that drug 419 will reduce the acute locomotor activity and the sensitization caused
by administration of nicotine.
In order to understand the effects of drug 419 on locomotor sensitization, nicotine will be
given as a control and drug 419 will be administered. The low doses of nicotine cause locomotor
stimulation and leads to release of dopamine in the nucleus accumbens, as well as progressive
increase in locomotor activity over days. After the same dose of nicotine is given daily it will
cause sensitization and modify the nicAChR antagonist and dopamine transporter (DAT)
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inhibition. The two groups of 6 adult rats of each sex were tested and each rat was tested in a 2’
by 2’ open-field box apparatus for locomotor activity (Omnitech). In the sensitization period,
each rat was given SC injection of 0.5 mg/Kg nicotine, prepared in a sterile saline solution and
after the sensitization each rat received either the vehicle DMSO/saline (10% v/v) or the drug
419 (25 mg/Kg) SC injection. The behavior was recorded in the Omnitech box for pre and post
sensitization. The locomotor activity was recorded, and the experiment was repeated 3 to 5 days
later with the opposite compound to see what effect drug 419 has in rats. The experimental
design and protocols were followed by the researchers and the staff at the DLAR to help
maintain the effects of drug 419 on locomotor activity and to limit any errors in the locomotor
model.
Procedure
The locomotor sensitization model was used for this study and adapted to understand
how the adult rats will react to nicotine and drug 419, respectively. This experiment was a sixday locomotor sensitization model that used 12 rats at 2 to 6 months of age and were grouped
into sex of male and female. The rats were grouped based on sex and separated into groups at the
start of the experiment. At least one week before experimentation began, each rat was housed in
a standard plastic rat box with rodent bedding, standard rodent chow, and water provided by ad
libitum. All the rats were housed in the same room, with the same ambient temperature, and had
the 12-hour light/12-hour dark cycle prior to testing. These procedures helped the rats have
sufficient acclimation to housing conditions before any experimentation.
Before starting any experimentation, the rats were given time to acclimate to the
environment and to reduce stress by having researchers handle the rats. The rats were divided in
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to two groups of six adult SD rats of each sex (male = 6, female = 6) for the experiment. Each rat
will be tested individually in a 2ft by 2ft open-field box apparatus for locomotor activity. The
boxes are made by Omnitech and located in Combs room 119 in BBSRB at University of
Kentucky. The low dose of nicotine is prepared at 0.5 mg/Kg in a sterile saline injection that is
administered acutely via the subcutaneous route to the adult rats. The low doses of nicotine will
cause locomotor stimulation that will release dopamine in the nucleus accumbens and lead to
sensitization as nicotine is administered daily for 5 days. The locomotor activity in the Omnitech
box was recorded for two hours with an acclimation time of one hour in the box before
experimentation. In between animals each box apparatus is cleaned with Clorox hydrogen
peroxide disinfectant solution and the Shepherd’s Specialty absorbent techboard paper is
replaced at the bottom of the box.
In the first “sensitization” part of the experiment, each rat was given a daily 0.5 mg/Kg
nicotine via SC injection for 5 days. Then the rats were placed in the locomotor activity box
apparatus for 2 hours and the locomotion was recorded. The locomotion activity for all 12 rats
was recorded and noted in the protocol binder for record keeping. The use of this locomotion
recording allowed researchers to establish a baseline and understand how the rats responded over
the 5-day period, as well as the rat’s activity. After the sensitization period, the experiment was
conducted with the same rats to observe what difference will occur. The rats were given the same
dose of nicotine injection and after 20 minutes were given a SC injection of either the vehicle
DMSO/saline (10% v/v) or the drug 419 vehicles (of 25 mg/Kg). The administer is blinded as to
what drug each animal got, and this allowed for observing what difference occurred in the
locomotor activity. The behavior in the Omnitech activity monitors is recorded for two hours.
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The animals were not measured for blood nicotine nor drug 419 concentration but only for
locomotor activity.
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Experiment 3: Effects of 419 on conditioned place preference (CPP)
Purpose
Lobinaline-N-bioxide (419) may have certain pharmacological benefits if given at correct
doses and here, we examine how it can affect rats in conditioned place preference (CPP). The use
of drug 419 will help examine the effects of how inherent rewarding properties can be altered
due to the drug response in the CPP paradigm. The administration of drug 419 will change how
drug rewarding consumption behavior in rats can become altered in the CPP paradigm. The
literature will focus on how drug 419 will affect reward potential in vivo in adolescent rats via
the use of conditioned place preference paradigm.
Animal and Housing
Male Sprague-Dawley rats (n=6; commercial vendor [Envigo], transferred to University
of Kentucky) and Female Sprague-Dawley rats (n=6; commercial vendor [Envigo], transferred to
University of Kentucky) were used. Rats ranged in age from 2 to 6 months old and weighed from
200 g to 350 g at the start of the study. Each rat was given a unique identification (tail markings)
for dosing and experimental use for study records. The use of the unique identification allowed
for proper dosing and documentation for study records. The rats had access to food and water in
home cages for the duration of the experiment. The procedures were performed in accordance
with the appropriate standard operating procedures in use by “University of Kentucky Division
of Laboratory Animal Resources (DLAR)”, and this is fully accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC).
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These adolescent rats were chosen for the study due to the usefulness and acceptances of
this model in lab research. The reason for only 12 rats is because this is the minimum necessary
amount to get valid scientific results for this study. This study did not duplicate any previous
work and does not unnecessarily replicate any previous work. The procedures used in this study
are to help avoid and minimize any stress, pain, or discomfort to the animals. Although there
were no animals in distress from this study however, if any animals experienced any pain or
distress, they were to be painlessly euthanized by the consultation of the University of Kentucky
veterinary stuff or Study Director.
The animals were also housed in proper plastic boxes with soft bedding and maintained
in a 12-hour light/12-hour dark cycle at University of Kentucky DLAR facility. The rooms were
temperature-controlled and humidity-controlled rooms from 64 °F to 84 °F and 30% to 70%,
respectively. The boxes had enrichment items in them and were maintained on a regular basis.
The 12 rats were not randomized, each mouse received the same test article at the same dose and
had the same route of administration of drug 419. When the animals arrived at the DLAR they
were given a period of about a week to get acclimated to the surroundings before any
experimentation occurred. The animals were also observed periodically during this acclimation
time to make sure no adverse or distress occurred in any of the animals. The animals were also
acclimated to handlers and researches during this one-week time. During the study there were no
control groups, but each mouse will receive the same doses and route of administration of drug
419 and the control to be 10% DMSO/saline.
The animals were fed a standard, commercial diet of Harlan Teklad Global 18% protein
rodent diet. The local tap water was available ad libitum via automated watering bottles or
watering systems. From the experiment it is reasonable to state that no contaminants were
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suspected in the diet or water that would have affected the outcome of the experiments. At the
end of the study the animal will be kept till data analysis is complete. After completion of data
analysis, the animals will be offered to UK research community before euthanasia is
administered.
Euthanasia
If any animal or animals showed any signs of distress due to unpredicted side effects
from 419, they are to be euthanized immediately and reported to the Study Director. These
animals will be euthanized by using pentobarbital sodium overdose (>100 mg/kg). The animal
residual carcasses will be disposed of by the University of Kentucky Division of Laboratory
Animal Resources. If in the event any animal distress is observed during the study both the
Director and Sponsor were notified.
Drug
There were sufficient quantities of lobinaline-N-bioxide (419) that was provided by
Naprogenix Inc (Lexington, KY). When the test article arrived at University of Kentucky, it was
inventoried and stored under desiccation at -20°C or as instructed by Naprogenix Inc. The drug
419 was provided to the University of Kentucky at the GLP Neuroscience center in Lexington,
Kentucky. The route of administration for this drug was subcutaneously (SC) and all protocols
recommended by DLAR and UKY procedure were adhered to. The drug 419 is diluted with a
10% DMSO/saline to be able to be administered. In order to understand the effects of how drug
419 plays a role conditioned place preference (CPP), drug 419 will be administered by SC
injections of 25 mg/Kg prepared in a 1 ml/Kg injection volume. The use of a control vehicle will
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be implemented which is DMSO/saline (10% v/v) injection to observe how the rats respond to
the CPP.
Statistical Analyses
All the data sets will be analyzed on how ethanol was consumed and analyzed via the
two-way Analysis of Variance (ANOVA) with Bonferroni post-hoc comparisons. The ANOVA
will show the repeated measures with all 3 days vs 419 vs control in CPP. The data will show
what the P-value is, the matching effectiveness and baseline repeated measure ANOVA. All tests
will be statistical significance at p<0.05.
Study Modifications and Record Retention
During the study if the need for any modification occurred it was made with verbal or
written consent by the Study Director. If verbal authorization was given it was documented in the
raw data and was followed with a written protocol amendment within 10 business days. If the
need for any amendments or deviations occurred to the study protocol it was documented, dated,
signed by the Study Director, and maintained in the study protocol. If any of these amendments
needed to occur, it was also approved by the Sponsor. When the issuance of the final report to
the Study Sponsor, all the raw data and specimens relating to the study generated by University
of Kentucky are retained for up to 1 year in the test facility archives. The test facility archives
staff will contact the Sponsor after 1 year to determine the disposition of the archived materials.
Portions of the study conducted by the sponsor or sponsor’s designee will be archived in the
storage facilities of the sponsor or sponsor’s designee.
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Experimental Design
In many studies the most used test for testing how animals respond and behave to drug
abuse is conditioned place preference (Vastola et al., 2002). The conditioned place preference
(CPP) is a behavioral concept that helps researchers understand and measure drug reward in
laboratory animals (Vastola et al., 2002). CPP is helpful because it allows for researchers to test
animals in a drug-free state and measure locomotor activity (Vastola et al., 2002). The use of
CPP will allow for assessment of locomotor activity without requiring the animals to have
extended periods of training the CPP paradigm (Vastola et al., 2002). In this experiment design,
the CPP will play an important role in electing different results in how rats will respond to no
drug compartment versus drug 419 nonpreferred compartment (Vastola et al., 2002). The use of
CPP will play an important role because of the two distinct compartments and the Pavlovian
form of learning due to the distinct visual and texture cues that are repeatedly paired with the
drug 419. The effects of drug 419 in the CPP paradigm will show how the rats respond to the
dose and if the results will show if the rewarding properties of drug 419 are present. We believe
that the drug 419 will have a rewarding efficacy and will be confirmed from the locomotor
stimulation/ activity during the CPP.
In order to understand the effects of drug 419 on locomotor stimulation and activity the
use of CPP is critical. The low doses of drug 419 should have an effect when paired with the
correct chamber and with conditioned pairing taking place. Since drug 419 should have some
rewarding properties, the rats should spend more time in the chamber associated with the drug.
The behavior and place of choice will be recorded in the CPP box for pre and post SC injection
of drug 419. The CPP chambers will be recorded and the experiment will be repeated with
control versus drug 419 administration. The experimental design and protocols were followed by
33

the researchers and the staff at the DLAR to help maintain the effects of drug 419 on CPP and to
limit any errors in the CPP model.
Procedure
The CPP model was used for this study and adapted to understand how the rats reacted to
drug 419. This experiment used the CPP standard paradigm and placed each of SD adults’ rats in
CPP chambers to see what the outcome will be. This experiment was a six-day CPP model that
used 12 rats at 2 to 6 months of age and were grouped into sex of male and female. The rats were
grouped based on sex and separated into groups at the start of the experiment. At least one week
before experimentation began, each rat was housed in a standard plastic rat box with rodent
bedding, standard rodent chow, and water provided by ad libitum. All the rats were housed in the
same room, with the same ambient temperature, and had the 12-hour light/12-hour dark cycle
prior to testing. These procedures helped the rats have sufficient acclimation to housing
conditions before any experimentation.
Prior to any experimentation, the rats were given time to acclimate to the environment
and to reduce stress by having researchers handle the rats. The rats were divided in to two groups
of six adult SD rats of each sex (male = 6, female = 6) for the experiment. Each rat will be tested
individually in a CPP chamber (Med-Associates). The chambers are in BBSRB at University of
Kentucky. In the habituation procedure, the animals were given a chance to explore the CPP
apparatus, to reduce the effects of novelty. The habituation was consistent with one to two trials
of approximated five minutes exploration over two separate days. The CPP chambers have
“white” and “black” compartments that are not divided by anything and this allowed for the
animals to prefer the compartments. In order to understand which, compartment the animal will
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adjust to, each animal was given time over separate days and each animal had 3 to 4 trials on
average. This pre-screen habituation allowed to see which animals have preference to which
compartment and to understand where the drug 419 will be administered. Typically, the rats will
prefer the black compartment and the drug 419 will be used in the “least preferred” white
compartment.
On day one of conditioning trials, each rat was each injected with drug 419 at a dose of
25 mg/kg via S.C. in a 1 mL/kg injection volume. The rats were then placed in the “least
preferred” chamber for 20 minutes. On the condition trial of day two, the rats were each given a
control injection of DMSO/saline 10% v/v via S.C. in 1 mL/kg injection volume. The same
pairing was then repeated for conditioning days 3 and 4, then again on days 5 and 6. This three
repeated pairing of drug 419 versus control allowed for attaining average CPP preferences.
During the testing process, the animals had access to the entire CPP chamber and the behavior
was recorded. While placed in the CPP chambers the animal’s activity was recorded to the
computer that had the software program Med-PC IV in the BBSRB at University of Kentucky.
The duration for each animal while in the CPP chambers was assessed for a 20-minute test
session. During this experimentation, the administrator is blinded to what vehicle each animal
got. The animals were not measured for blood levels nor drug 419 concentration but only for
CPP chamber habituation activity.
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Chapter III
Results
In this study we understood and investigated the interaction of lobinaline-N-bioxide (419)
on alcohol consumption, nicotine locomotor effects, and conditioned place preference in rats and
mice. The three behavioral experiments and models that were implemented all gave new insight
of how lobinaline-N-bioxide (419) affects rats and mice. The results for each of the following are
listed below.
Experiment 1 Effects of 419 on alcohol consumption (DID)
The results from alcohol consumption versus administration of drug 419 were analyzed
and examined to see what effect drug 419 had. The use of drinking in the dark model gave
insight on how drug 419 may affect alcohol consumption. From the DID model the male and
female mice received ethanol for 6 days. By giving the mice ethanol for 6 days it allowed for
mice to acclimate to the environment and gave baseline ethanol consumption. By measuring the
amount of ethanol consumption each mouse had it provided evidence for how the baseline would
vary. Initially, we planned to do 4 days of ethanol consumption, but after observing the data it
was found that 6 days gave better baseline ethanol consumption. Furthermore, the baseline data
gave a good comparison to observe how the mice will react to after administration of drug 419.
We found that being blinded to the chemical injection in each mice group created
different results. From the data it was observed that female mice received ethanol alone for 6
days and then received drug 419 on the 7 day. After the 7 day the female mice received the
th
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control vehicle, which was on the 8 day. This data can be seen in figure 2 in the middle graph,
th
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which includes all the females in each day. The results suggest that some female mice consumed
more ethanol than others and each day some mice drank more than other days. This created some
baseline ethanol consumption variability and indicates high variability for each female mouse.
The reason for this could be a cyclical pattern as observed in most animal models.
In the male mice, the data shows how each male mouse got ethanol for six consecutive
days and then received a vehicle on the 7 day. After the 7 day the male mice received drug 419,
th
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which was on the eight day. This introduction of the vehicle on the 7th day created some
randomization and gave different results than that of the female group. In figure 2, in the lower
graph, it can be observed that on average the male mice tend to drink more ethanol at the
baseline with a high variable ethanol consumption. Furthermore, the male mice consumed near
the same amount of ethanol when given the vehicle but drank less ethanol when given drug 419.
In the top graph of figure 2, it seems that overall, the administration of drug 419 may have small
effects, but cannot be conclusive because of variations in amount of ethanol consumed.
To find a better correlation, we used only day six as a baseline for consumption of
ethanol, as seen in figure 3. The need to use only day six as a baseline was to understand if being
acclimated to ethanol will show any differences between day 6 consumption, vehicle
administration, and drug 419 administration. In figure 3, the top graph shows some indication
that drug 419 may have helped, but upon closer examination it seems that some mice respond to
the drug differently than others, as seen by the connecting lines. Figure 3 also shows variation in
each male and female mice group. When analyzing figure 3 it seems that female mice on average
had smaller amounts of ethanol consumption when drug 419 was administered. However, when
the vehicle was administered it had no significant changes or very small changes to ethanol
consumption. Regarding the male mice in figure 3, the administration of drug 419 did have a
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small change but so did the vehicle. This indicates that the changes are not significant and drug
419 may not be influencing alcohol consumption as we assumed.
To get a better understanding of the effect drug 419 has on alcohol consumption we
examined 4-day averages of ethanol consumption. We examined the data and used the mean of
days 3, 4, 5, and 6, baseline ethanol consumption, as seen in figure 4. We converted the test days
consumption to see if drug 419 is active or not. In figure 4, it can be assumed that there seems to
be a very small change in ethanol consumption after administration of drug 419. It appears that
drug 419 does decrease the amount of ethanol consumption that either female or male mice
consume. This shows that there is plausible indication of how drug 419 may help in reducing the
consumption of ethanol. Furthermore, in figure 4, when looking at the male mice it seems that
some male mice did have drastic changes of ethanol consumption and did better than when the
vehicle was administered. However, in female mice it seems that drug 419 did have a small
reduction in amount of ethanol consumption but does not correlate well when examining the
vehicle.
The alcohol consumption of drinking in the dark model gave results that were helpful but
did not provide significant results. From the supplemental data and figures it seems that the
effect of drug 419 did not influence ethanol consumption. The figures show that, although some
small changes are present, the vehicle provides the same effect. This indicates that the vehicle
and drug 419 seem to have the same effects. However, this could be because of the low dose of
419 we administered to the mice or if the act of SC injection had a physiological response in the
mice. Furthermore, it seems that the mechanism of action for drug 419 needs to be further
studied. It would also help to examine what dose of drug 419 may evoke a response in the male
and female mice. Finally, based on these findings, it seems that the selected dose of drug 419
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may be a challenge for attaining neurobehavioral changes in mice for treating alcohol
consumption.
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Figure 2: Consumption of EtOH day-by-day in mice. See supplemental data for more
information.
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Figure 3: Effects of 25 mg/Kg of 419 on EtOH consumption using the only day 6 as the
baseline consumption in mice. See supplemental data for more information.
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Figure 4: Effects of 25 mg/Kg of 419 on EtOH consumption using 4 days for the baseline
consumption in mice. See supplemental data for more information.
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Experiment 2 Effects of 419 on nicotine locomotor sensitization
In this experiment we administered drug lobinaline-N-bioxide (419) and nicotine to
examine the effects in vivo neurobehavioral tests in rats. We administered drug 419 via SC
injection in rats at a low dose, as well as varenicline (nicotine) at low dose to see the effects in
the nicotine-locomotor sensitization model. The effects on nicotine-induced locomotor activity
(LMA) were examined when low doses of nicotine were administered daily for five days during
the experiment phase. Figure 5 shows how each male rat was given nicotine daily and it can be
observed that there are four male rats that have some reversal tendencies. In figure 5 it is evident
that four of the six male rats had a decrease in nicotine induced LMA after the administration of
drug 419. In figure 6 it indicates that males did have a progressive increase in LMA activity over
the 5 days. This is due to the release of dopamine from the mesolimbic pathway causing the
response to be positive and have increase locomotor activity due to nicotine.
In figure 6, on day 6 with the administration of drug 419 the male rats show a decrease in
nicotine LMA activity. The slope and plateau that is indicated in figure 5 and 6 indicate that drug
419 may have an effect in reversing nicotine induced LMA, but the increase activity levels
eventually level off. This indicates that lobinaline-N-dioxide may reduce the effects of nicotine
by helping reduce dopamine and acetylcholine release by inhibiting the reward circuity. The use
of drug 419 in nicotine locomotor sensitization shows how important it is as a future drug to help
possible reduce nicotine addiction. However, it must be noted that it would have help to do have
another day of testing with drug 419 to see a better result and to be certain the effects of drug 419
are correlated. Furthermore, this experimental design is underpowered and would benefit if
repeated.
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Figure 7 shows how each female rat was given nicotine daily and shows the increase
tendencies in locomotor sensitization. In figure 7 it is evident that all six female rats had an
increase in nicotine induced LMA and show progressive sings of LMA. In figure 8, on day 6 the
administration of drug 419 indicates that the female rats have a reversal in nicotine induced
LMA. From figure 8, it can be inferred that all the female rats respond well to drug 419 and had
a decreased in nicotine induced LMA.
The use of the nicotine locomotor sensitization model gave good data as indicated in
figures 5, 6, 7, and 8, respectively. The use of nicotine showed how progressively linear the
increases in nicotine-induced locomotor activity occurred due to sensitization for days one
through five. The administration of drug 419 on day six shows that there is a reversal in LMA in
both rat groups. This experimental design clear indicates that drug 419 is effective in helping
treat nicotine induced LMA, as observed by the repeated measures in ten out of the twelve
animals. However, due to the experiment being underpowered and not being fully repeated it
should be noted that this is just a small indication on how drug 419 may affect LMA. The
predictive value of drug 419 from this experiment indicates that it could potential be a
therapeutic in treating nicotine use disorder.

44

Figure 5: Daily nicotine-induced locomotor activation over days 1-5 in male rats. See
supplemental data for more information.

Figure 6: Nicotine-induced locomotor activation average in male rats. See supplemental data
for more information.
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Figure 7: Daily nicotine-induced locomotor activation over days 1-5 in female rats. See
supplemental data for more information.

Figure 8: Nicotine-induced locomotor activation average in female rats. See supplemental data
for more information.
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Experiment 3 Effects of 419 on conditioned place preference (CPP)
In this experiment we administered drug lobinaline-N-bioxide (419) and examined the
effects in vivo neurobehavioral tests in rats. We administered drug 419 via subcutaneous route in
rats at a low dose to see the effects in the CPP model. The low doses of drug 419 does not cause
the rats to spend more time in the drug administered compartment. This behavior of the rats was
showing how binary the outcome will be because either the rats are going to the preferred
compartment or not after conditioning. The use of CPP allowed for proper screening of potential
value for the use of drug 419.
Table 1 shows how the rats in each group responded to drug 419 in the CPP model. Here
it can be seen that each rat did on average, of three days of conditioning, prefer a certain
compartment. All the rats had spent time in each compartment and the average of the time spent
in either black or white compartment was calculated. There is no order nor trend for which
compartment that the rats preferred and hence the prediction that the rats prefer black
compartment prior to experimentation was not valid. Furthermore, there seems to be no
difference in male versus female rats as to what compartment each sex prefer, but habituation
was consistent to the preferred compartments.
When the three days of conditioning placement ended, the rats were given drug 419 in the
least preferred compartment. Each of the rats had a different compartment preference and data
was recorded in Table 1. The days that the rats were given injection of DMSO/saline 10% v/v is
noted and it did not provide any valid information.
From Table 1 it seems that there are not significant results to show how drug 419 effect
the CPP model. It was observed that out of the 12 rats used for the experiment only 3 rats had
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some effect and that the other 9 rats went to their preferred compartment. This shows that drug
419 did not have a significant effect as we had hoped for in the CPP model and that drug 419
does not cause any changes in the neurobehavior of rats. Furthermore, it also shows that drug
419 may not be a proper drug for abuse regarding the CPP model in rats and the need for
repeating the experiment with different dose may be needed.
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Table 1: CPP chart for Males and Females Rats
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Chapter IV
Discussion
In this study we examined the effects of drug lobinaline-N-bioxide (419) on alcohol
consumption, nicotine locomotor effects, and conditioned place preference in rats and mice. Here
we documented for the first time how drug lobinaline-N-bioxide (419) may not be an effective
drug 419 in each of the models. We anticipated for lobinaline-N-bioxide to have direct or
indirect effects in the models on alcohol consumption, nicotine locomotor effects, and CPP. Our
current results show that drug 419 at the dose we administered does not seem to have a
significant effect in the mesolimbic dopaminergic pathways and may not facilitate a role in
treating drug abuse. Our interest was to understand how drug 419 may help with inhibiting DAT,
reward neural circuitry, and ultimately drug abuse. From the results it is evident that there needs
to be a better pharmacological understanding of drug 419 before the behavioral tests can be
considered conclusive. The present results show that there does not seem to be significant results
and that dose dependence may play a role. The effect of drug 419 is not accurately represented
because of the dose response and future studies need to better examine how it may play a role in
drug abuse.
Our results from in vivo alcohol consumption and administration of drug 419 show that
the effects of drug 419 is not significant. This is because the amount of ethanol that the mice
consumed had variable results and the effects of the drug 419 versus the vehicle did not yield
good results. However, when examining just the 4-day averages of baseline alcohol consumption
versus drug 419, it does show some small changes. This requires the need to examine the
pharmacokinetics and dose response of drug 419 in mice. The dose of drug 419 that we
administered may not show a significant response, but future studies could examine at what dose
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a response would occur. To our knowledge, this is the first study that examined how effective
drug 419 is regarding alcohol consumption in the dark. The need to examine how effective drug
419 regarding alcohol consumption could also be tested in rats or other animal models, if the
pharmacokinetics of the drug are better understood. Further research is required to better
understand the effectiveness of drug 419 with changing neurobehavior of alcohol consumption.
In the study of nicotine locomotor sensitization model, the results show that drug 419 has
the potential to possible be an effective drug. The nicotine locomotor sensitization model shows
how drug 419 had trends that reduced the effects of nicotine. The use of nicotine showed how
progressively linear the increases in nicotine-induced locomotor activity occurred in the rats due
to sensitization. The administration of drug 419 shows a trend that there is a reversal in LMA in
both male and female rat groups. This experimental design gave quality information on how drug
419 has the potential for treating nicotine use disorder. This is the first study to examine how
drug 419 may help in reversing nicotine induced locomotor activity. However, the need to
examine how effective 419 is in treating nicotine drug abuse is still necessary before drawing
any conclusion. Future studies will need to examine if the effects of drug 419 can last longer than
a day and if it has the same effect in larger sample size.
In the CPP model, it was evident that the rats did not alter their neurobehavior and went
to their preferred compartment. This could be because of the low dose that drug 419 was
administered at and that it was a binary approach. It also might have been an issue with rats not
being randomly assigned to black or white compartments and an error in compartment
preferences could have risen. The use of CPP showed that rats did not have a reduction in the
time of least preferred compartment but, rather went back to their preferred compartment. The
post-conditioning test also showed that the rats had a preferred compartment. The results for CPP
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show that there is no significant statistical analysis and there is no difference between preferred
to non-preferred compartments both in pre and post condition for the rats. It seems evident that
in this study the use of drug 419 in the CPP model is not supported by the idea of
neurobehavioral changes in rats. Further research needs to examine how a different dose of drug
419 may alter the behavior and if the steps in the CPP model can be altered to force rats to have a
preferred compartment when administering drug 419.
Limitations
In most studies there are certain limitations that make it hard to get significant results.
This study also had limitations such as sample size, difference between rats versus mice, the dose
of drug 419, breed differences, and sex differences that may have hindered the ability to get
significant data. In this study, we had a small sample size overall that made it hard to get good
data. The ability to get a greater sample size would have increased the effects of drug 419, but
the cost of maintaining and caring for the animals would also increase. There is a size difference
between rats and mice regarding body weight and this may alter the correct dose each animal
would need. In addition, the mice are much smaller and tend to have higher metabolic rate than
rats, thus the metabolism of drug 419 may be faster in mice than in rats.
Most novel drugs need to thoroughly examine for pharmacokinetics, physiological
effects, dose response, and toxicity. Regarding drug 419, the dose we chose may not have been
the right dose to elicit an adequate dose response. The drug 419 could have caused a low reaction
that we are not aware of because of the low dose administered. The amount of drug 419 that was
administered in this study could have been a baseline dose and thus did not cause a significant
effect.
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Many studies have examined to see if there is a difference between rat breeds that may
affect neurobehavioral activity (Deehan et al., 2018). It has been noted that various breeds of rat
lines tend to have genetic predisposition for high alcohol preferences and may have different
brain reward pathways (Deehan et al., 2018). There is a difference between selective breeding
and thus, some breeds exhibiting addictive disorders (Deehan et al., 2018). There also seems to
be a difference between Wistar rats and non-alcohol-preferring rats causing a genetic difference
in drug-induced changes (Deehan et al., 2018).
In many studies most of the work is conducted on male animals and this may play a role
in sex differences. Many studies show that there are sex differences in drug addiction, and this
may cause male and female rats to respond differently (Orsini et al., 2016). In female rats, the
estrous cycle may play a role in influencing behavior (Orsini et al., 2016). This may alter the
ability to fully understand how drugs affect male versus female rats. It has been found that
sensitivity to dopamine neurotransmission in male and female rats does affect behavior (Orsini et
al., 2016). Furthermore, it has been found that female rats tend to progress from drug use to
dependence much quicker than male rats (Orsini et al., 2016). Thus, in our study it may be
possible that drug 419 had different effects in male versus female rats and given us inconclusive
evidence.
Future Directions
Future work will have to uncover the correct dose of drug 419 to cause a drug response
and examine how drug 419 affects both alcohol and nicotine. It has been found that different
breeds of rats tend to exhibit addictive behaviors and may be predisposed to drug abuse (Deehan
et al., 2019). Furthermore, there may be a possible difference in rats and mice on alcohol
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consumption (Deehan et al., 2011). It is evident that different rat breeds do consume different
amounts of ethanol indicating that selective breeding may play a role (Deehan et al., 2011). This
shows that the types of phenotype rats and different breeds of rats that are used in experiments
do play a role. Future studies need to examine how alcohol consumption plays a role in different
breed types and determine the correct type of rat breed for interaction with drug 419.
Further research needs to examine if the dose of drug 419 can be altered to give an illicit
or addicting reaction in the nicotine locomotor sensitization model. The need to examine how the
combination of drug 419/nicotine, saline/nicotine, and saline/saline may affect nicotine-induced
locomotor sensitization models (Fredrickson et al., 2003). The activity of the three types of drug
combination may play a role in how locomotor activity changes and how dopamine levels may
be altered (Fredrickson et al., 2003). This would give a better understanding of how nicotine
dependence can develop and how this would be altered by injection of drug 419/nicotine
combination in locomotor activity.
Finally, further studies could benefit to see how drug lobinaline truly alters brain activity
by using fMRI. The use of fMRI would allow for attaining how the rat brain responds to drug
lobinaline, as well as understanding what regions are associated with the mesolimbic reward
pathway (Wellman et al., 2012). The fMRI would allow for visualizing any changes that may
occur in the brain when giving drug 419 before and after administration. This would pave the
way for identifying and mapping what correlation exists with lobinaline and the mesolimbic
pathway.
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Supplemental Data and Statistical Analysis
Alcohol Consumption (Drinking-in-the-Dark)

Statistical analysis results:

Repeated measures one-way anova with all 6 days vs 419 vs vehicle
Table Analyzed

day by day
All

Repeated measures ANOVA summary
Assume sphericity?

No

F

12.97

P value

<0.0001

P value summary

****

Statistically significant (P < 0.05)?

Yes

Geisser-Greenhouse's epsilon

0.5597

R square

0.4809

Was the matching effective?
F

6.094

P value

<0.0001

P value summary

****

Is there significant matching (P < 0.05)?

Yes

R square

0.3112

ANOVA table

SS

DF

MS

F (DFn, DFd)

P value

Treatment (between columns)

516.2

7

73.75

F (3.918, 54.85) =
12.97

P<0.0001

Individual (between rows)

485.1

14

34.65

F (14, 98) = 6.094

P<0.0001

Residual (random)

557.2

98

5.686

Total

1558

119

Data summary
Number of treatments (columns)

8

Number of subjects (rows)

15

Number of missing values

0

As you can see from the values below it is clear that depending on the “baseline” we choose. we have an
effect vs 419 and even vs vehicle but not 419 vs the vehicle.
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Multiple comparison results
Number of families
Number of
comparisons per
family
Alpha

1
28

0.05

Tukey's multiple
comparisons test

Mean
Diff.

95.00% CI of diff.

Significant?

Summary

Adjusted
P Value

Day 1 vs. Day 2

-1.087

-4.757 to 2.584

No

ns

0.9586

A-B

Day 1 vs. Day 3

-4.547

-8.373 to -0.7204

Yes

*

0.0152

A-C

Day 1 vs. Day 4

-6.593

-8.874 to -4.313

Yes

****

<0.0001

A-D

Day 1 vs. Day 5

-3.260

-6.460 to -0.05987

Yes

*

0.0445

A-E

Day 1 vs. Day 6

-2.847

-5.993 to 0.2993

No

ns

0.0896

A-F

Day 1 vs. TA-A

-0.8600

-4.277 to 2.557

No

ns

0.9825

A-G

Day 1 vs. Vehicle

-1.140

-4.528 to 2.248

No

ns

0.9230

A-H

Day 2 vs. Day 3

-3.460

-5.747 to -1.173

Yes

**

0.0020

B-C

Day 2 vs. Day 4

-5.507

-8.416 to -2.597

Yes

***

0.0002

B-D

Day 2 vs. Day 5

-2.173

-5.236 to 0.8893

No

ns

0.2687

B-E

Day 2 vs. Day 6

-1.760

-5.882 to 2.362

No

ns

0.7925

B-F

Day 2 vs. TA-A

0.2267

-2.586 to 3.039

No

ns

>0.9999

B-G

-0.05333

-3.412 to 3.305

No

ns

>0.9999

B-H

Day 3 vs. Day 4

-2.047

-5.311 to 1.218

No

ns

0.3997

C-D

Day 3 vs. Day 5

1.287

-1.542 to 4.116

No

ns

0.7408

C-E

Day 3 vs. Day 6

1.700

-2.533 to 5.933

No

ns

0.8355

C-F

Day 3 vs. TA-A

3.687

0.9815 to 6.392

Yes

**

0.0050

C-G

Day 3 vs. Vehicle

3.407

0.09335 to 6.720

Yes

*

0.0419

C-H

Day 4 vs. Day 5

3.333

0.4037 to 6.263

Yes

*

0.0210

D-E

Day 4 vs. Day 6

3.747

1.148 to 6.345

Yes

**

0.0031

D-F

Day 4 vs. TA-A

5.733

2.996 to 8.471

Yes

****

<0.0001

D-G

Day 4 vs. Vehicle

5.453

2.786 to 8.120

Yes

****

<0.0001

D-H

Day 5 vs. Day 6

0.4133

-2.918 to 3.745

No

ns

0.9998

E-F

Day 5 vs. TA-A

2.400

-0.3415 to 5.142

No

ns

0.1068

E-G

Day 5 vs. Vehicle

2.120

-1.028 to 5.268

No

ns

0.3218

E-H

Day 6 vs. TA-A

1.987

-0.8728 to 4.846

No

ns

0.2896

F-G

Day 6 vs. Vehicle

1.707

-0.4081 to 3.821

No

ns

0.1588

F-H

Day 2 vs. Vehicle
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TA-A vs. Vehicle

-0.2800

-1.841 to 1.281

No

ns

0.9976

G-H

Test details

Mean 1

Mean 2

Mean Diff.

SE of diff.

n1

n2

q

DF

Day 1 vs. Day 2

5.660

6.747

-1.087

1.040

15

15

1.477

14

Day 1 vs. Day 3

5.660

10.21

-4.547

1.084

15

15

5.930

14

Day 1 vs. Day 4

5.660

12.25

-6.593

0.6463

15

15

14.43

14

Day 1 vs. Day 5

5.660

8.920

-3.260

0.9069

15

15

5.084

14

Day 1 vs. Day 6

5.660

8.507

-2.847

0.8915

15

15

4.516

14

Day 1 vs. TA-A

5.660

6.520

-0.8600

0.9684

15

15

1.256

14

Day 1 vs. Vehicle

5.660

6.800

-1.140

0.9602

15

15

1.679

14

Day 2 vs. Day 3

6.747

10.21

-3.460

0.6481

15

15

7.550

14

Day 2 vs. Day 4

6.747

12.25

-5.507

0.8245

15

15

9.445

14

Day 2 vs. Day 5

6.747

8.920

-2.173

0.8679

15

15

3.541

14

Day 2 vs. Day 6

6.747

8.507

-1.760

1.168

15

15

2.131

14

Day 2 vs. TA-A

6.747

6.520

0.2267

0.7970

15

15

0.4022

14

Day 2 vs. Vehicle

6.747

6.800

-0.05333

0.9518

15

15

0.07925

14

Day 3 vs. Day 4

10.21

12.25

-2.047

0.9251

15

15

3.129

14

Day 3 vs. Day 5

10.21

8.920

1.287

0.8017

15

15

2.270

14

Day 3 vs. Day 6

10.21

8.507

1.700

1.200

15

15

2.004

14

Day 3 vs. TA-A

10.21

6.520

3.687

0.7666

15

15

6.801

14

Day 3 vs. Vehicle

10.21

6.800

3.407

0.9390

15

15

5.131

14

Day 4 vs. Day 5

12.25

8.920

3.333

0.8302

15

15

5.678

14

Day 4 vs. Day 6

12.25

8.507

3.747

0.7364

15

15

7.195

14

Day 4 vs. TA-A

12.25

6.520

5.733

0.7758

15

15

10.45

14

Day 4 vs. Vehicle

12.25

6.800

5.453

0.7558

15

15

10.20

14

Day 5 vs. Day 6

8.920

8.507

0.4133

0.9442

15

15

0.6191

14

Day 5 vs. TA-A

8.920

6.520

2.400

0.7769

15

15

4.369

14

Day 5 vs. Vehicle

8.920

6.800

2.120

0.8921

15

15

3.361

14

Day 6 vs. TA-A

8.507

6.520

1.987

0.8103

15

15

3.467

14

Day 6 vs. Vehicle

8.507

6.800

1.707

0.5993

15

15

4.027

14

TA-A vs. Vehicle

6.520

6.800

-0.2800

0.4424

15

15

0.8950

14
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Stats results for using 4-day average as a baseline vs 419 vs vehicle
We averaged 4 days of baseline (days 3-6) per animal to obtain the same number of data points per
column to do a repeated measure ANOVA.

Average 4 days for RM anova

20
15
EtOH

10
5
0

419
Baseline
avg 4 Days
M-F

vehicle

Results:
Table Analyzed

Average 4 days for
RM anova

Repeated measures ANOVA
summary
Assume sphericity?
F
P value
P value summary

No
26.80
<0.0001
****
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Yes

Statistically significant (P <
0.05)?
Geisser-Greenhouse's epsilon

0.9200

R square

0.6568

Was the matching effective?
F

8.812

P value

<0.0001

P value summary

****

Is there significant matching (P
< 0.05)?

Yes

R square

0.6019

ANOVA table

SS

DF

MS

F (DFn, DFd)

P value

Treatment (between columns)

109.9

2

54.96

F (1.840, 25.76) = 26.80

P<0.0001

Individual (between rows)

253.0

14

18.07

F (14, 28) = 8.812

P<0.0001

Residual (random)

57.43

28

2.051

Total

420.4
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Data summary
3

Number of treatments
(columns)
Number of subjects (rows)

15

Number of missing values

0

Multiple comparison
Number of families

1

Number of comparisons per 3
family
Alpha

0.05

Tukey's multiple
comparisons test

Mean Diff.

95.00% CI of diff.

Significant?

Summary

Adjusted P
Value

Column A vs. 419

3.447

2.028 to 4.865

Yes

****

<0.0001

A-B

Column A vs. vehicle

3.167

1.661 to 4.672

Yes

***

0.0002

A-C

419 vs. vehicle

-0.2800

-1.438 to 0.8779

No

ns

0.8048

B-C
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Test details

Mean 1

Mean 2

Mean Diff.

SE of diff.

n1

n2

q

DF

Column A vs. 419

9.967

6.520

3.447

0.5420

15

15

8.993

14

Column A vs. vehicle

9.967

6.800

3.167

0.5753

15

15

7.785

14

419 vs. vehicle

6.520

6.800

-0.2800

0.4424

15

15

0.8950

14
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Figure 1 : Consumption of EtOH day-by-day
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Figure 2: Effects of 25 mg/Kg of 419 on EtOH consumption using the only day 6 as the baseline consumption.
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Figure 3 : Effects of 25 mg/Kg of 419 on EtOH consumption using 4 days for the baseline consumption
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Stats ANOVA for males results

Table Analyzed
Repeated measures
ANOVA summary
Assume sphericity?
F
P value
P value summary
Statistically significant (P
< 0.05)?
Geisser-Greenhouse's
epsilon
R square
Was the matching
effective?
F
P value
P value summary
Is there significant
matching (P < 0.05)?
R square
ANOVA table
Treatment (between
columns)
Individual (between
rows)
Residual (random)
Total
Data summary
Number of treatments
(columns)
Number of subjects
(rows)
Number of missing
values

Males
column
Horiz
activuty

No
10.26
0.0004
***
Yes
0.6510
0.6724

13.97
<0.0001
****
Yes
0.4780
SS

DF

325045718

5

442675588
158392741
926114047

5
25
35

MS F (DFn, DFd)
F (3.255,
16.28) =
65009144
10.26
F (5, 25) =
88535118
13.97
6335710

6
6
0
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P value
P=0.0004
P<0.0001

Stats ANOVA for males Multiple comparison
Number of families
Number of
comparisons per
family
Alpha

1
15
0.05

Tukey's multiple
comparisons test
Day 1 vs. Day 2
Day 1 vs. Day 3
Day 1 vs. Day 4
Day 1 vs. Day 5
Day 1 vs. Column F
Day 2 vs. Day 3
Day 2 vs. Day 4
Day 2 vs. Day 5
Day 2 vs. Column F
Day 3 vs. Day 4
Day 3 vs. Day 5
Day 3 vs. Column F
Day 4 vs. Day 5
Day 4 vs. Column F
Day 5 vs. Column F
Test details
Day 1 vs. Day 2
Day 1 vs. Day 3
Day 1 vs. Day 4
Day 1 vs. Day 5
Day 1 vs. Column F
Day 2 vs. Day 3
Day 2 vs. Day 4
Day 2 vs. Day 5
Day 2 vs. Column F
Day 3 vs. Day 4
Day 3 vs. Day 5
Day 3 vs. Column F
Day 4 vs. Day 5
Day 4 vs. Column F
Day 5 vs. Column F

Mean Diff.
-4353
-5893
-5786
-9634
-7806
-1541
-1433
-5282
-3454
107.8
-3741
-1913
-3849
-2021
1828
Mean 1
7034
7034
7034
7034
7034
11386
11386
11386
11386
12927
12927
12927
12819
12819
16668

Adjusted
95.00% CI of
diff. Significant? Summary P Value
-10695 to 1990
No
ns 0.1795
-13481 to 1694
No
ns 0.1224
-10205 to -1366
Yes
* 0.0168
-16472 to -2796
Yes
* 0.0123
-13766 to -1846
Yes
* 0.0168
-8608 to 5527
No
ns 0.9223
-7164 to 4298
No
ns 0.8762
-11294 to 731.2
No
ns 0.0805
-10737 to 3830
No
ns 0.4379
-6175 to 6390
No
ns >0.9999
-8639 to 1158
No
ns 0.1293
-9581 to 5756
No
ns 0.8772
-9359 to 1662
No
ns 0.1705
-4453 to 411.6
No
ns 0.0978
-4979 to 8635
No
ns 0.8451
Mean 2 Mean Diff. SE of diff.
n1
11386
-4353
1487
6
12927
-5893
1779
6
12819
-5786
1036
6
16668
-9634
1603
6
14840
-7806
1397
6
12927
-1541
1657
6
12819
-1433
1343
6
16668
-5282
1409
6
14840
-3454
1707
6
12819
107.8
1473
6
16668
-3741
1148
6
14840
-1913
1798
6
16668
-3849
1292
6
14840
-2021
570.2
6
14840
1828
1596
6
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A-B
A-C
A-D
A-E
A-F
B-C
B-D
B-E
B-F
C-D
C-E
C-F
D-E
D-F
E-F
n2
q
6 4.140
6 4.686
6 7.898
6 8.499
6 7.902
6 1.315
6 1.509
6 5.299
6 2.861
6 0.1035
6 4.607
6 1.505
6 4.213
6 5.012
6 1.620

DF
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5

Stats ANOVA for Females (results)

Table Analyzed
Repeated measures
ANOVA summary
Assume sphericity?
F
P value
P value summary
Statistically significant (P <
0.05)?
Geisser-Greenhouse's
epsilon
R square
Was the matching
effective?
F
P value
P value summary
Is there significant
matching (P < 0.05)?
R square
ANOVA table
Treatment (between
columns)
Individual (between rows)
Residual (random)
Total
Data summary
Number of treatments
(columns)
Number of subjects (rows)
Number of missing values

Females column
Horiz activuty

No
6.936
0.0068
**
Yes
0.5025
0.5811

5.387
0.0017
**
Yes
0.3110
SS
393203598
305432929
283469169
982105696

DF

MS

5 78640720
5 61086586
25 11338767
35

6
6
0
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F (DFn, DFd)
F (2.513, 12.56) =
6.936
F (5, 25) = 5.387

P value
P=0.0068
P=0.0017

Stats ANOVA for Females Multiple comparison
Number of
families
Number of
comparisons per
family
Alpha

15
0.05

Tukey's multiple
comparisons test

Mean
Diff.

Day 1 vs. Day 2
Day 1 vs. Day 3
Day 1 vs. Day 4
Day 1 vs. Day 5
Day 1 vs. Column F
Day 2 vs. Day 3
Day 2 vs. Day 4
Day 2 vs. Day 5
Day 2 vs. Column F
Day 3 vs. Day 4
Day 3 vs. Day 5
Day 3 vs. Column F
Day 4 vs. Day 5
Day 4 vs. Column F
Day 5 vs. Column F

1

Adjusted P
95.00% CI of
Value
diff. Significant? Summary
-12267 to -6579
890.8
Yes
*
0.0282
-5910 -14052 to 2232
No
ns
0.1517
-3977 -13758 to 5805
No
ns
0.5657
-20522 to -10607
691.5
Yes
*
0.0385
-8005 -20104 to 4095
No
ns
0.1996
669.2 -8270 to 9609
No
ns
0.9992
2602 -6627 to 11831
No
ns
0.8207
-4028 -11490 to 3435
No
ns
0.3351
-1426 -9204 to 6353
No
ns
0.9594
1933 -4180 to 8046
No
ns
0.7535
-4697 -11784 to 2391
No
ns
0.1986
-2095 -11616 to 7426
No
ns
0.9198
-6630 -12253 to -1007
Yes
*
0.0261
-4028 -13022 to 4967
No
ns
0.4855
2602 -1939 to 7143
No
ns
0.2913

Test details
Mean 1
Day 1 vs. Day 2
14360
Day 1 vs. Day 3
14360
Day 1 vs. Day 4
14360
Day 1 vs. Day 5
14360
Day 1 vs. Column F 14360
Day 2 vs. Day 3
20939
Day 2 vs. Day 4
20939
Day 2 vs. Day 5
20939
Day 2 vs. Column F 20939
Day 3 vs. Day 4
20270
Day 3 vs. Day 5
20270
Day 3 vs. Column F 20270
Day 4 vs. Day 5
18337
Day 4 vs. Column F 18337
Day 5 vs. Column F 24966

Mean 2 Mean Diff. SE of diff.
20939
-6579
1333
20270
-5910
1909
18337
-3977
2293
24966
-10607
2324
22364
-8005
2836
20270
669.2
2096
18337
2602
2163
24966
-4028
1749
22364
-1426
1823
18337
1933
1433
24966
-4697
1661
22364
-2095
2232
24966
-6630
1318
22364
-4028
2109
22364
2602
1064
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n1
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6

A-B
A-C
A-D
A-E
A-F
B-C
B-D
B-E
B-F
C-D
C-E
C-F
D-E
D-F
E-F
n2
q
6 6.978
6 4.379
6 2.453
6 6.454
6 3.991
6 0.4516
6 1.701
6 3.256
6 1.106
6 1.908
6 3.998
6 1.327
6 7.113
6 2.701
6 3.457

DF
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5

Conditioned Place Preference (CPP)
Condition place preference (CPP) data

Males

81
08
18
81
08
19
81
08
20
81
08
21
81
08
22
81
08
23

day 1
Blac Whit
k
e

day 2
day 3
Blac Whit Blac
k
e
k

Total
counts
Whit Blac
e
k

Whit
e

Post
conditio
ning
Blac
k

Whit
e

Preferre
d

8.6

9.7

6.7

9.8

8.2

9.2

23.5

28.7

5.7

14.1

Y

7.9

14.2

6.3

12.1

11.2

9

25.4

35.3

9.9

11

Y

5.28

4.8

9.1

8.42

9.4

9

23.7
8

22.2
2

11.1

13.6
9

N

8

6.5

14.5

7.7

13.7

7.4

36.2

21.6

13.2

8.5

Y

4.6

1.2

3.7

1.2

4.2

0.7

12.5

3.1

10

3.1

Y

5

4.2

10

8.1

8.1

7.2

23.1

19.5

17

4.5

Y

9.79

34

37.5
9

7.8

12

Y

10.3

29.3

29.8

5.8

8.1

Y

10.1

19

32

11.2

10.8

N

6

45.5

16.5
4

18.2

8

Y

4.1

26.6

8.5

9.9

11.7

N

7

43.6

26.8

31

8.3

Y

Fe
m
ale
s
81
08
24 11.5 16.2 11.3 11.6 11.2
81
08
25 10.6 10.3
9
9.2
9.7
81
08
26
6.9
9.6
6.2 12.3
5.9
81
08
27 14.3
4.24 11.5
6.3 19.7
81
08
9.5
2.1 10.5
2.3
6.6
28
81
08
29 13.2 11.4 13.3
8.4 17.1
9 out of 12 went to their preferred box
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